| NCT number | Study status | Phase of trial | Tumor entity | Drug | Irradiation regimen | First pdsted |
| NCT02298946 | Has results | Phase 1 | Metastatic Colorectal cancer | Anti-PD1 (AMP-224) | SBRT1 × 8 Gy or 3 × 8 Gy | 2014.11.24 |
| NCT02434081 | Has results | Phase 2 | NSCLC III期 | Anti-PD1 (Nivolumab) | RT | 2015.5.5 |
| NCT03115801 | Has results | Phase 2 | Metastatic genitourinary cancers | Anti-PD1 (Nivolumab/ Atezolizumab/ Pembrolizumab) | IMRT/IGRT3 × 10 Gy | 2017.4.14 |
| NCT03220854 | Has results | Phase 2 | Solid tumor | Anti-PD1 | SBRT 18~60 Gy/3~5 f | 2017.7.18 |
| NCT03988647 | Has results | Phase 2 | Metastatic merkel cell carcinoma | Anti-PD1 (Pembrolizumab) | RT 3 × 9 Gy or 5 × 4~6 Gy | 2019.6.17 |
| NCT02303990 | Has results | Phase 1 | Metastatic cancers | Anti-PD1 (Pembrolizumab) | HFRT 3 × 8 Gy-1 × 17 Gy | 2014.12.1 |
| NCT02759575 | Has results | Phase 1/2 | Head and neck cancer | Anti-PD1 (Pembrolizumab) | RT 35 × 2 Gy | 2016.5.3 |
| NCT03051672 | Has results | Phase 2 | Metastatic breast cancer | Anti-PD1 (Pembrolizumab) | RT 5 × 4 Gy | 2017.2.14 |
| NCT03465891 | Has results | Phase 2 | Lymphoma | Anti-PDL1 (atezolizumab) | RT 2 × 2 Gy | 2018.3.14 |
| NCT02311361 | Has results | Phase 1/2 | Pancreatic cancer | Anti-PDL1 (Durvalumab) Anti-CTLA4 (Tremelimumab) | SBRT 1 × 8 Gy or 5 × 5 Gy | 2014.12.8 |
| NCT02934503 | Has results | Phase 2 | SCLC | Anti-PD1 (Pembrolizumab) | Thoracic radiotherapy | 2016.12.17 |
| NCT03617913 | Has results | Phase 2 | Bladder cancer | Anti-PDL1 (avelumab) | RT | 2018.8.7 |
| NCT02952586 | Has results | Phase 3 | Squamous cell carcinoma of the head and neck | Anti-PDL1 (avelumab) | IMRT 35 × 2 Gy | 2016.9.2 |
| NCT02336165 | Has results | Phase 2 | glioblastoma | Anti-PDL1 (Durvalumab) | RT 30 × 2 Gy | 2015.1.12 |
| NCT02221739 | Has results | Phase 1/2 | NSCLC | Anti-CTLA4 (ipilimumab) | RT 5 × 6 Gy-3 × 9.5 Gy | 2014.8.20 |
| NCT01449279 | Has results | Phase 2 | melanoma | Anti-CTLA4 (ipilimumab) | RT | 2011.10.10 |
| NCT01769222 | Has results | Phase 1/2 | Melanoma/ non-hodgkin lymphoma/colon/ rectal | Anti-CTLA4 (ipilimumab) | RT 3 × 10 Gy | 2013.1.16 |
| NCT02701400 | Has results | Phase 2 | Recurrent SCLC | Anti-PDL1 (Durvalumab) Anti-CTLA (Tremelimumab) | SBRT 3 × 9 Gy | 2016.3.8 |